NEW ORLEANS, LA – A huge congratulations to Dr. Deirdre Hooper and her exceptional team at Audubon Dermatology for randomizing the first patient in a Phase 2 urticaria trial, a significant milestone in advancing care for patients with chronic skin conditions.

This achievement reflects not only swift and effective site activation but also Dr. Hooper’s strong leadership and longstanding commitment to high-quality clinical research. First-patient-in status is a notable benchmark in any study, signaling a high level of preparedness, patient trust, and operational excellence, hallmarks of Dr. Hooper’s clinical team.

Dr. Hooper, alongside her practice partner Dr. Sarah Jackson, has been a valued research partner with DelRicht Research for several years. Together, they have participated in more than 60 clinical trials as Principal Investigators and Sub Investigators, contributing to innovative dermatology research that spans acne, psoriasis, atopic dermatitis, vitiligo, and now urticaria. Their contributions have helped shape new treatment pathways and provide patients with access to emerging therapies.

Urticaria, or chronic hives, can significantly affect a patient’s comfort, confidence, and daily quality of life. By enrolling early in this Phase 2 trial, Dr. Hooper and her team are playing a critical role in evaluating the safety and efficacy of a new treatment that may offer hope for patients who have exhausted other options.

DelRicht Research is proud to recognize principal investigators like Dr. Deirdre Hooper and the team at Audubon Dermatology for their continued excellence, patient-first approach, and leadership in dermatology research. Their work is helping to move medicine forward and ensure that patients have access to the latest advancements in care.

Thank you, Dr. Hooper, for your ongoing dedication and partnership. We look forward to the continued progress of this important study.